Researchers divided 615 patients into a placebo group and a statin group. Among the group given statins, acute kidney injury occurred in 21 percent of individuals, compared to 19.5 percent in the placebo group. Patients in the statin group who had never received the drug previously experienced acute kidney injury 22 percent of the time, as opposed to 13 percent among patients who had.
“This double-blinded, placebo-controlled randomized clinical trial found no evidence that high-dose perioperative atorvastatin reduces the incidence or severity of acute kidney injury following cardiac surgery,” the authors concluded. “Among patients naïve to statin treatment, high-dose perioperative atorvastatin increased serum concentrations of creatinine, and there was some evidence that statin treatment may increase acute kidney injury among patients naive to statin treatment with preexisting chronic kidney disease … These results do not support the initiation of statin therapy to prevent acute kidney injury following cardiac surgery.”
More articles on quality:
What can hospitals do to take a stand against antibiotic resistance? Inside the University of Chicago Medical Center’s stewardship program
The rise of the patient sitter — one of healthcare’s most undervalued safety tools
Acute respiratory distress syndrome frequently goes unrecognized in ICUs
